PMID- 10391423
OWN - NLM
STAT- MEDLINE
DCOM- 19990910
LR  - 20220410
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 19
IP  - 6
DP  - 1999 Jun
TI  - Monitoring unfractionated heparin therapy with antifactor Xa activity results in 
      fewer monitoring tests and dosage changes than monitoring with the activated 
      partial thromboplastin time.
PG  - 760-6
AB  - STUDY OBJECTIVE: To determine how much more costly it is to monitor 
      unfractionated heparin (UFH) therapy by antifactor Xa heparin activity (HA) than 
      by activated partial thromboplastin time (aPTT). DESIGN: Prospective, randomized, 
      unmasked, cohort, single-center study. SETTING: A 625-bed, adults-only, private 
      teaching hospital. PATIENTS: Two hundred sixty-eight patients with a variety of 
      indications for UFH therapy. INTERVENTIONS: Patients were treated with UFH based 
      on ideal weight (75 U/kg bolus, 20 U/kg initial infusion) and monitored by either 
      HA or aPTT, MEASUREMENTS AND MAIN RESULTS: After adjusting for gender, groups 
      were equivalent in patient characteristics and UFH dosage. The HA group had fewer 
      monitoring tests and dosage changes/24 hours than the aPTT group. These 
      reductions neutralized much of the increased cost of the HA assay itself. 
      CONCLUSION: Monitoring UFH therapy over 96 hours with an HA assay costs $4.37 
      more than monitoring with aPTT. This modest increase may be acceptable given 
      other advantages of the HA assay.
FAU - Rosborough, T K
AU  - Rosborough TK
AD  - Medical Education Department, Abbott Northwestern Hospital, Minneapolis, 
      Minnesota 55407, USA.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Anticoagulants/*administration & dosage/blood
MH  - Cohort Studies
MH  - Drug Monitoring/*economics/*standards
MH  - *Factor Xa Inhibitors
MH  - Female
MH  - Heparin/*administration & dosage/blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Prospective Studies
EDAT- 1999/07/03 00:00
MHDA- 1999/07/03 00:01
CRDT- 1999/07/03 00:00
PHST- 1999/07/03 00:00 [pubmed]
PHST- 1999/07/03 00:01 [medline]
PHST- 1999/07/03 00:00 [entrez]
AID - 10.1592/phco.19.9.760.31547 [doi]
PST - ppublish
SO  - Pharmacotherapy. 1999 Jun;19(6):760-6. doi: 10.1592/phco.19.9.760.31547.